A PHASE II DOSE-ESCALATION STUDY TO ASSESS THE FEASIBILITY AND SAFETY OF TRANSENDOCARDIAL DELIVERY OF THREE DIFFERENT DOSES OF ALLOGENEIC MESENCHYMAL PRECURSOR CELLS (MPCS)IN SUBJECTS WITH HEART FAILURE: